






FIG. 1A



3/15




FIG. 1F




FIG. 1E




FIG. 1D




FIG. 2

5/15




FIG. 3A

SUBSTITUTE SHEET (RULE 26)

6/15

Tube Name: 02-Well-D5
Sample ID:

Population	Events	% Total	% Parent
▼  All Events	347706	100.00%	100.00%
▼  Lymph	88221	25.37%	25.37%
▼  CD4+ T cells	18815	5.41%	21.33%
▼  Tregs	506	0.15%	2.69%
 CCR5+ Treg	96	0.03%	18.97%

FIG. 3B

7/15

(A) Subject 1: Representative images of IHC for CCR5




FIG. 4A

(B) Negative Control CCR5




FIG. 4B

(C) Positive Control CCR5




FIG. 4C

SUBSTITUTE SHEET (RULE 26)

Patient D	
Breast Cancer (Breast Cancer) – Clinical Stage IV T.P. = Time Point (AJCC v8) (TNM: cM1; ER Status: Negative; PR Status: Negative)	
A; 42 yo Stage IV Metastatic breast CA triple negative to Lung/hilar LN dx after completing ddAC-->taxol Negative BRCA T.P.A. presented with cough and chest xray with 2.4 cm R perihilar mass. CT chest T.P.B 2.5 cm R hilar soft tissue density and R hilar adenopathy PETCT with RUL lung nodule and R hilar LN SUV== No liver, bone mets T.P.C. s/p EBUS and biopsy =breast primary GATA 3 positive, CK20 negative and TTF1 negative. Er negative <1% PR negative <1% and HER2 IHC negative 0 Pending PD1 testing T.P.D Brain MRI negative Mammogram TOMO T.P.E normal and US normal T.P.E labs Vid d 33 CMP normal CBC normal	
PLAN T.P.I Dacardron 4 BID started T.P.G and IV today with Carbo densitization today on Triple negative cytodyn trial. Will continue steroids post x 3 days T.P.H PETCT reviewed and continued response target lung lesion 2.1 x 1.6 cm (from 2.4x1.9 just on T.P.F) SUV down significantly from 15 to 6. Having some fasting glucose elevations with steroids as fasting glucose for PET was 120, Did have some gestational diabetes managed with diet. Will avoid Xmas sweets and check at home am/pm.	
26% reduction in tumor size	

FIG. 5

9/15

Patient A						
CHEST						
Date	A	B	C	D		
Time point A	1.8 x 1.6 cm	3.2 x 2.3 cm	2.2 x 1.4 cm	1.2 x 1.1 cm		
Time point B	1.3 x 1.0 cm	2.5 x 2.3 cm	1.6 x 1.0 cm	1.1 x 0.9 cm		
Time point C	1.2 x 0.9 cm	2.0 x 1.7 cm	1.5 x 0.7 cm	0.7 x 0.6 cm		
Time point D	1.8 x 1.0 cm	2.3 x 1.1 cm	1.1 x 0.5 cm	0.6 x 0.6 cm		
Time point E	1.4 x 0.7 cm	2.8 x 1.3 cm		0.6 x 0.6 cm		
Time point F	Unchanged	2.6 x 1.0 cm	1.1 x 0.4 cm	6 mm		
Time point G	1.8 x 1.1 cm					
Time point H	1.8 x 1.2 cm	2.6 x 1.0 cm	4 mm	5 mm		
Time point I	2.5 x 2.2 cm	2.6 x 0.9 cm	4 mm	5 mm		
Time point J	2.6 x 2.2 cm	2.7 x 0.8 cm				
Time point K	Extra 5 mm					
Time point L	Extra 6 mm					
Time point M	Extra 7 mm					
A=Inferior right breast lesion B=Left upper lobe nodule C=Left upper lobe nodule D=Right lower lobe nodule						
LIVER--Time Point F at least 6 lesions are seen.						
Date	1--largest	2	3	4	5	6
Time point A	5.8 x 4.2 cm					
Time point B	5.2 x 2.2 cm					
Time point C	3.5 x 1.2 cm					
Time point D	3.1 x 1.3 cm					
Time point E	Unchanged					
Time point F	Unchanged					
Time point G	Stable					
Time point H	Unchanged					
Time point I	Treated hepatic metastases are slightly decreased in conspicuity on today's					
Time point J	Multiple treated metastases remain small and scar like					

FIG. 6

SUBSTITUTE SHEET (RULE 26)

10/15

Patient A CCR5 Time Point #1						
				tube 2		
		Number of CTCs		0		
		Number of Apoptotic CTCs		0		
		Number of EMTs		0		
		Number of CAMLs		17		
		Largest CAML		111 μ m		
	<u>CCR5 INT</u>	<u>CCR5 Background</u>	<u>CCR5 expression</u>	<u>CCR5 score</u>	<u>Number of CCR5 Dots</u>	<u>CAML size</u>
CAML	402	233	169		6	34
CAML	562	230	332		34	38
CAML	303	233	70		13	60
CAML	332	227	105		16	56
CAML	292	232	60		14	57
CAML	296	226	70		10	71
CAML	360	222	138		23	33
CAML	288	225	63		18	47
CAML	307	219	88		5	34
CAML	304	215	89		24	100
CAML	280	210	70		13	47
CAML	644	285	359		8	38
CAML	375	214	161		11	105
CAML	296	212	84		6	79
CAML	309	224	85		40	111
CAML	612	494	118		16	79
CAML	338	245	93		31	63

FIG. 7A

SUBSTITUTE SHEET (RULE 26)


11/15

Patient A PD-L1 Time Point #1					
				tube 1	
		Number of CTCs		0	
		Number of Apoptotic CTCs		0	
		Number of EMTs		0	
		Number of CAMLs		17	
		Largest CAML		219 μ m	
	PDL1 INT	PDL1 Background	PDL1 expression	PDL1 score	CAML size
CAML	432	260	172	1	219
CAML	443	233	210	1	62
CAML	416	227	189	1	73
CAML	420	255	165	1	88
CAML	911	272	639	2	31
CAML	295	195	100	1	201
CAML	476	259	217	1	53
CAML	443	269	174	1	147
CAML	388	274	114	1	39
CAML	299	223	76	1	45
CAML	298	223	75	1	61
CAML	475	241	234	1	34
CAML	355	245	110	1	45
CAML	337	223	114	1	52
CAML	397	223	174	1	66
CAML	350	300	50	1	70
CAML	351	228	123	1	207


FIG. 7B

SUBSTITUTE SHEET (RULE 26)


12/15




Patient A - image 1-CCR5




Patient A - image 2-CCR5



Patient A - image 3-CCR5



Negative control CCR5



Positive control CCR5

FIG. 8

SUBSTITUTE SHEET (RULE 26)

13/15

30 60
TCTAGACCACCATGAAGTTGCCTGTTAGGCTGTTGGTGCTGATGTTCTGGATTCTGCTT
M K L P V R L L V L M P W I P A

90 120
CCAGCAGTGATATTGTGATGACCCAATCTCCACTCTCCCTGCCTGTCCTCCTGGAGAOC
S S S D I V M T Q S P L S L P V T P G E

150 180
CAGCCTCCATCTCTTGCAGATCTAGTCAGCGCCTTCTGAGCAGTTATGGACATACCTATT
P A S I S C R S S Q R L L S S Y G H T Y

210 240
TACATTGGTACCTACAGAAGCCAGGCCAGTCTCCACAGCTCCTGATCTACGAAGTTTCCA
L H W Y L Q K P G Q S P Q L L I Y E V S

270 300
ACCGATTTTCTGGGGTCCCAGACAGGTTTCAGTGGCAGTGGGTCAGGGACAGATTTACAC
N R F S G V P D R F S G S G S G T D F T

330 360
TTAAGATCAGTAGAGTGGAGGCTGAGGATGTGGGAGTTTATTACTGCTCTCAAAGTACAC
L X I S R V E A E D V G V Y Y C S O S T

390 420
ATGTTCTCTCTCACGTTCCGACAGGGGACCAAGGTGGAAATAAAACGTAAGTAGTCTTCTC
H V P L T P G Q G T K V E I K (SEQ. ID NO: 1)

429
AACTCTAGA (SEQ. ID NO: 2)

FIG. 9

SUBSTITUTE SHEET (RULE 26)

14/15

30 39
ACGCGTCCACCATGGAATGGAGCGGAGTCTTTATCTTTCTCCTGTCAGTAACTGCAGGT
M E W S G V F I F L L S V T A G

89 118
GTCCACTCCGAGGTGCAGCTGGTGGAGTCTGGTGGAGGCTTGGTAAAGCCTGGAGGTTTC
V H S E V Q L V E S G G G L V K P G G S

148 177
CCTTAGACTCTCCTGTGCAGCCTCTGGTTACACTTTTCAGTAACTATTGGATCGGATGGG
L R L S C A A S G Y T F S N Y W I G N

207 236
TCCGCCAGGCTCCAGGCCAAGGGCTCGAGTGGATTGGCGATATCTACCCCTGGAGGGAAC
V R Q A P G K G L E W I G D I Y P G G N

266 295
TACATCAGGAACAATGAGAACTTCAAGGACAAGACCACCCCTGTCAGCAGATACTTCCAA
Y I R N N E K F K D K T T L S A D T S K

325 354
GAACACAGCCTATCTGCAAATGAACAGCCTGAAAACCGAGGACACAGCCGTGTATTACT
N T A Y L Q M N S L K T E D T A V Y Y

384 413
GTGGAAGCAGCTTCGGTAGTAACTACGTGTTTCGCTGGTTTACTTACTGGGGCCAAAGGG
C G S S F G S N Y V F A W F T Y W G Q G

443 457
ACTCTGGTCACAGICTCCTCAGGTGAGTCCTTAAACCTCTAGA (SEQ. ID NO: 4)
T L V T V S S (SEQ. ID NO: 3)

FIG. 10

SUBSTITUTE SHEET (RULE 26)

15/15

30 60
TCTAGACCACCATGGAATGGAGCGSSGGTCTTTATCTTTCTCCTGTCAGTAACTGCAGGTG
M E W S G V F I F L L S V T A G

90 120
TCCACTCCCAGGTCCAACTGGTGCACTCTGGACCTGATGTGAAAAAGCCTGGGACTTCAR
V H S Q V Q L V Q S G P D V K K P G T S

150 180
TGAAGATGTCCTGCAAGACGTCTGGATACACCTTCAGTAACTATTGGATCGGATGGGTTA
M K M S C K T S G Y T F S N Y W I G W V

210 240
GGCAGGCGCCTGGACAAGGCCTTGAGTGGATTGGAGATAPTTACCCTGGAGGGAACTATA
R Q A P G Q G L E W I G D I Y P G G N Y

270 300
TCAGGAACAATGAGAAGTTCAAGGACAAGACCACACTGACGGCAGACACATCGACCAGCA
I R N N E K F R D K T T L T A D T S T S

330 360
CGGCCTACATGCAACTTGGCAGCCTGAGATCTGAAGACACTGCCGCTCTATTACTGTGGAA
T A Y M Q L G S L R S E D T A V Y Y C G

390 420
GCAGCTTCGGTAGTAACTACGTGTTGCGCTGGTTTACTTACTGGGGCCAAGGGACTCTGG
S S F G S N Y V F A N F T Y W G Q G T L

450 457
TCACAGTCTCCTCAGGTGAGTCCTTAAAACCTCTAGA (SEQ. ID NO: 6)
V T V S S (SEQ. ID NO: 5)

FIG. 11

SUBSTITUTE SHEET (RULE 26)